Completed PHASE4 INTERVENTIONAL 3-arm NCT04054492

To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV

A Randomized, Multi-center, Controlled Clinical Trial for Evaluating the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV

Sponsor: China National Biotec Group Company Limited

Conditions Reaction - Vaccine Vaccination

Interventions Sabin-IPV+Sabin-IPV+Sabin-IPV Sabin-IPV+Sabin-IPV+bOPV Sabin-IPV+bOPV+bOPV

Updated 5 times since 2019 Last updated: Aug 11, 2019 Started: Mar 1, 2018 Primary completion: Jan 25, 2019 Completion: Jun 12, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Reaction - Vaccine and Vaccination, this trial is completed. The trial is conducted by China National Biotec Group Company Limited and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Oct 2021 [monthly]

Completed PHASE4
Sep 2019 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China National Biotec Group Company Limited
Hubei Provincial Center for Disease Control and Prevention
Inner Mongolia Autonomous Region Center for Diseases Prevention and Control
Peking University
Shaanxi Provincial Center for Disease Control and Prevention

Data source: China National Biotec Group Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hohhot, China